S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

• Susan Bal,
• Jesus Berdeja,
• Myo Htut,
• Mehmet Kocoglu,
• Tara Gregory,
• Larry D. Anderson,
• Adriana Rossi,
• Daniel Egan,
• Luciano Costa,
• Lisa Kelly,
• Safiyyah Ziyad,
• Hongxiang Hu,
• Yanping Chen,
• Allison J. Kaeding,
• Michael Burgess,
• Kristen Hege,
• Omar Nadeem

Affiliations

Susan Bal

1 University of Alabama at Birmingham, Birmingham, United States

Jesus Berdeja

2 Sarah Cannon Research Institute, Nashville, United States

Myo Htut

3 City of Hope Comprehensive Cancer Center, Duarte, United States

Mehmet Kocoglu

4 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, United States

Tara Gregory

5 Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, United States

Larry D. Anderson

6 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Cellular Therapy and Hematologic Malignancies Program, Dallas, United States

Adriana Rossi

7 Icahn School of Medicine at Mount Sinai, New York, United States

Daniel Egan

8 Swedish Cancer Institute, Seattle, United States

Luciano Costa

1 University of Alabama at Birmingham, Birmingham, United States

Lisa Kelly

9 Bristol Myers Squibb, Princeton, United States

Safiyyah Ziyad

9 Bristol Myers Squibb, Princeton, United States

Hongxiang Hu

9 Bristol Myers Squibb, Princeton, United States

Yanping Chen

9 Bristol Myers Squibb, Princeton, United States

Allison J. Kaeding

9 Bristol Myers Squibb, Princeton, United States

Michael Burgess

9 Bristol Myers Squibb, Princeton, United States

Kristen Hege

9 Bristol Myers Squibb, Princeton, United States

Omar Nadeem

10 Dana-Farber Cancer Institute, Boston, United States